A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph(+)) chromosome carrying the BCR-ABL oncogene, a constitutively active tyrosine kinase. The discovery of imatinib represents a major success story in the treatment against CML. However, mutations in the BCR-ABL kinase domain are a major...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Liuya, Yang, Yang, Gupta, Pranav, Wang, Aihong, Zhao, Min, Zhao, Yao, Qu, Mei, Ke, Yu, Liu, Ying, Liu, Hong-Min, Xu, Xin, Sun, Yanli, Chen, Zhe-Sheng, Hu, Zhenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341061/
https://www.ncbi.nlm.nih.gov/pubmed/32671189
http://dx.doi.org/10.1016/j.omto.2020.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341061/
https://www.ncbi.nlm.nih.gov/pubmed/32671189
http://dx.doi.org/10.1016/j.omto.2020.06.008

Ejemplares similares